RECOVERY pre-print out.
In hypoxic hospitalised COVID-19 patients requiring either no oxygen or simple oxygen only, higher dose corticosteroids significantly increased the risk of death compared to usual care, which included low dose corticosteroids.https://t.co/01RDdO4Gfc
This has been an excellent collaboration with new insights into immunogenicity of #COVID-19 vaccines in inflammatory bowel disease https://t.co/65b2nDV44r
A midweek night out with an educational twist. Fast paced and fun evening at the #pride Lates | Science Museum with @robin_shattock talking about #HIV#vaccines for @eavi2020 https://t.co/FwIRUgvXdI
Excellent primer from @ajpollard1 A guide to vaccinology: from basic principles to new developments | Nature Reviews Immunology https://t.co/ZJTCpYAUdO
What’s next for an HIV #vaccine? After two days of exciting science at the #EAVI2020 meeting @robin_shattock explains why our innovative experimental medicine studies are needed to meet the challenge of developing an effective #HIV vaccine
I know that almost no-one in the UK wants to hear this, but the number of people being hospitalised who are +ve for COVID is increasing again (before anyone asks - we are seeing people admitted because of COVID, & not just incidental cases) 1/6
Happy #InternationalWomensDay2022! A day to celebrate and highlight the achievements of women in all aspects of life, we're marking the day by sharing some quotes from some of the amazing women working within @eavi2020 👏 #IWD2022#BreakTheBias 🙅♀️
We are looking for healthy volunteers to take part in our COVID-19 vaccine study. If you’re aged 30-55 and in good health contact the recruitment team by emailing [email protected] to find out more. You will be compensated up to £1010 for your time and inconvenience.
9/What’s next for COVAC1? In our next paper we will examine how the COVID-19 SARNA vaccine fares when given to more people with a bigger age range and with a longer gap between doses.
1/The initial paper from our trial of a self-amplifying RNA (SARNA) COVID-19 vaccine is out now. This is a first SARNA vaccine report in humans; what did we discover? @ImperialInfect@ImperialNHS @MRCCTU @robin_shattock @Dr_HMCheeseman
8/Where next for SARNA? Theoretically a low dose vaccine platform would have fewer side effects, scalability and the potential for multivalent products like flu vaccine. Realising this with a formulation that is immunogenic at low dose levels is the goal of next gen SARNA.